153 related articles for article (PubMed ID: 22300111)
1. Diagnostic incidence of the presence of positive HBsAg: epidemiologic, clinical, and virological characteristics.
Poves-Martínez E; del Pozo-Prieto D; Costero-Pastor B; Borrego-Rodríguez G; Beceiro-Pedroño I; Sanz-García C; Busteros-Buraza JI; González Palacios MR
Rev Esp Enferm Dig; 2012 Feb; 104(1):10-5. PubMed ID: 22300111
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the histological and serological parameters of patients with hepatitis delta virus in active and inactive hepatitis B virus carriers.
Shaikh S; Ram DB; Tanveer S; Talpur A
J Coll Physicians Surg Pak; 2014 Feb; 24(2):97-100. PubMed ID: 24491002
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.
Madejón A; Romero M; Hernández Á; García-Sánchez A; Sánchez-Carrillo M; Olveira A; García-Samaniego J
World J Gastroenterol; 2016 Mar; 22(11):3165-74. PubMed ID: 27003993
[TBL] [Abstract][Full Text] [Related]
6. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
8. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
9. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus and hepatitis C virus infections in Belgium: similarities and differences in epidemics and initial management.
De Vroey B; Moreno C; Laleman W; van Gossum M; Colle I; de Galocsy C; Langlet P; Robaeys G; Orlent H; Michielsen P; Delwaide J; Reynaert H; D'Heygere F; Sprengers D; Bourgeois S; Assene C; Vos B; Brenard R; Adler M; Henrion J; Deltenre P
Eur J Gastroenterol Hepatol; 2013 May; 25(5):613-9. PubMed ID: 23325285
[TBL] [Abstract][Full Text] [Related]
11. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
[TBL] [Abstract][Full Text] [Related]
12. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
13. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
[TBL] [Abstract][Full Text] [Related]
14. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
Yaşar DG; Suyanı E; Özenirler S; Sucak GT
Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
[TBL] [Abstract][Full Text] [Related]
15. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
16. Molecular epidemiology of hepatitis B and Delta virus strains that spread in the Mediterranean North East Coast of Tunisia.
Yacoubi L; Brichler S; Mansour W; Le Gal F; Hammami W; Sadraoui A; Ben Mami N; Msaddek A; Cheikh I; Triki H; Gordien E
J Clin Virol; 2015 Nov; 72():126-32. PubMed ID: 26513762
[TBL] [Abstract][Full Text] [Related]
17. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
18. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
[TBL] [Abstract][Full Text] [Related]
20. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
